Not only are soluble levels of uALCAM, and possibly CD6, a strong biomarker of disease, but therapeutic targeting of this pathway may provide an effective treatment for multiple pathologies of SLE, including skin and renal manifestations. Here, CD6 is linked to systemic lupus erythematosus.